Most Liquid Cancer Fighters Companies

Cash And Equivalents
Cash And EquivalentsEfficiencyMarket RiskExp Return
1REGN Regeneron Pharmaceuticals
7.02 B
(0.06)
 2.00 
(0.11)
2ARGX argenx NV ADR
2.6 B
(0.01)
 1.64 
(0.02)
3BDX Becton Dickinson and
1.42 B
 0.03 
 1.34 
 0.04 
4ZLAB Zai Lab
1.26 B
 0.16 
 3.22 
 0.51 
5NVCR Novocure
948.52 M
(0.24)
 2.88 
(0.70)
6BPMC Blueprint Medicines Corp
853.11 M
 0.01 
 3.49 
 0.03 
7HCM HUTCHMED DRC
829.71 M
 0.04 
 3.47 
 0.14 
8FGEN FibroGen
438.13 M
(0.03)
 9.08 
(0.28)
9IOVA Iovance Biotherapeutics
424.46 M
(0.27)
 4.21 
(1.12)
10CLDX Celldex Therapeutics
356.82 M
(0.11)
 2.99 
(0.34)
11INO Inovio Pharmaceuticals
348.13 M
 0.05 
 4.71 
 0.22 
12ATRA Atara Biotherapeutics
331.31 M
(0.06)
 9.16 
(0.53)
13PTCT PTC Therapeutics
288.43 M
 0.16 
 2.55 
 0.40 
14XBIT XBiotech
225.79 M
(0.08)
 4.24 
(0.35)
15MRSN Mersana Therapeutics
225.13 M
(0.18)
 8.78 
(1.62)
16GERN Geron
219.29 M
(0.15)
 5.34 
(0.83)
17AGEN Agenus Inc
218.23 M
(0.13)
 5.40 
(0.71)
18HALO Halozyme Therapeutics
209.36 M
 0.39 
 1.39 
 0.54 
19ADAP Adaptimmune Therapeutics Plc
199.67 M
(0.16)
 5.98 
(0.94)
20TGTX TG Therapeutics
195.71 M
 0.14 
 3.95 
 0.55 
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes. Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).